Recombinant Human Fibroblast growth factor receptor 2 (FGFR2), partial (Active)

1. The results showed no association between two SNPs, rs1219648 and rs2981582, and breast cancer risk, although in a stratified analysis rs2981582 strongly associated with premenopausal and ER-positive breast cancer in Chinese patients. PMID:30480917
2. The consequent appearance of the mesenchymal FGFR2c variant in the epithelial context would drive early steps of carcinogenesis. PMID:29068468
3. FGFR2 was shown to be markedly overexpressed in gastric cancer tissues and correlated with a high risk of lymph node metastasis and late clinical stage. FGFR2 was negatively associated with TSP4 and FGFR2 activation could downregulate TSP4 expression, which played an important role in the proliferation, invasion and migration of gastric cancer cells. PMID:30355943
4. In male breast cancer, smoking habits had a significant effect on overall survival at 10 years. In the same multivariate analysis, we found a significantly higher overall survival in cases with FGFR2 rs2981582 variant in the dominant transmission model A sensitivity analysis with left truncation showed similar results. PMID:29709729
5. Results showed that HER2 and FGFR2 are regulated by DDX6 at the post-transcriptional step in gastric cancer. PMID:29987267
6. High FGFR2 expression is associated with epithelial ovarian cancer cell proliferation and invasion. PMID:29970688
7. There is a wide spectrum of mutations in FGFR2 shown to be causative for Pfeiffer syndrome. Here we report the first Chinese three-generation family with FGFR2 mutation c.514_515delGCinsTT (p.Ala172Phe). PMID:29782338
8. It was concluded that miR494 inhibited the cancer initiating cells phenotype and reversed resistance to lapatinib by inhibiting FGFR2 in HER2positive gastric cancer. PMID:29786108
9. Patients with very strong FGFR2 mRNA expression showed more homogeneous FGFR2 mRNA expression compared to patients with lower FGFGR2 mRNA expression PMID:28852882
10. provide a comprehensive update on FGFR2-related syndromic craniosynostosis PMID:29230096
11. The mutations were not present in any of the unaffected family members or unrelated control subjects. These findings expand the mutation spectrum of FGFR2, and are valuable for genetic counseling in addition to prenatal diagnosis in patients with Crouzon syndrome. PMID:28901406
12. Fibroblast growth factor receptor 2 (FGFR2) splice site variants were identified in eight patients with Crouzon or Pfeiffer syndrome. PMID:26841243
13. Data suggest that the SOX9 transcription factor (SOX9)-fibroblast growth factor receptor 2 (FGFR2b) feed-forward loop has a lineage dependency role in pancreatic ductal adenocarcinoma (PDAC). PMID:28796141
14. this study reports for the first time the p.W290G mutation in patients with PS. Based on clinical features, genetic, and computational analysis and genotype-phenotype association studies PMID:28815901
15. Studies indicate that switching from fibroblast growth factor receptor 2 (FDFR-2) IIIb to IIIc variants correlates with the aggressiveness of the cancers via epithelial-mesenchymal transition [Review]. PMID:28930565
16. These results unveil the complexity of ER regulation by FGFR2-mediated signaling likely to be associated with BCa resistance to endocrine therapy. PMID:28869838
17. Study report that 5-10% of epidermal nevi harbor embryonic postzygotic FGFR2 activating mutations. PMID:27103312
18. this study identified an FGFR2 in two Chinese patients with syndromic craniosynostosis. The finding expands the reported mutation spectrum of FGFR2, and is of great value for genetic counseling and prenatal diagnosis in families with syndromic craniosynostosis. PMID:28849010
19. Through a stratification analysis, 5q11.2/MAP3K1 (rs16886034, rs16886364, rs16886397, rs1017226, rs16886448) and 7q32.3/LINC-PINT (rs4593472) were associated with Luminal A, and 10q26.1/FGFR2 (rs35054928) was associated with Luminal B. PMID:28408616
20. SNORD126 activates the PI3K-AKT pathway by upregulation of FGFR2. PMID:27913571
21. This study reveals a direct binding event and characterizes the role of TRPA1 ankyrin repeats in regulating FGFR2-driven oncogenic process; a mechanism that is hindered by miRNA-142-3p PMID:29038531
22. Although FGFR2 amplification is associated with poorer OS, it does not appear to be an independent prognostic predictor in patients with advanced gastric cancer treated with palliative fluoropyrimidine and platinum chemotherapy. PMID:27802183
23. This meta-analysis of case-control studies provides strong evidence that FGFR2 (rs2981582, rs2420946 and rs2981578) polymorphisms were significantly associated with the BC risk. PMID:27966449
24. we further refine the influence of variants in the FGFR2 locus with respect to molecular characteristics of breast tumors, in that they are more strongly associated with estrogen receptor status among cancers without amplification of the HER2 gene. PMID:27764800
25. Suggest FGFR2 as a novel acute myeloid leukemia susceptibility gene with a haplotype TT (rs7090018 and rs2912759) showing significant association with AML. PMID:27903959
26. Result demonstrated that FGFR2 high-expression was significantly associated with unfavorable prognosis of gastric adenocarcinoma and that SPRY2 could inhibit FGFR2-induced ERK phosphorylation and suppress FGFR2-elicited gastric cancer cell proliferation and invasion. PMID:28002800
27. By means of structural (X-ray and NMR) and functional characterization of pathogenic gain-of-function mutations affecting the FGF receptor (FGFR) tyrosine kinase domain, the authors elucidated a long-distance allosteric network composed of four interconnected sites termed the 'molecular brake', 'DFG latch', 'A-loop plug', and 'alphaC tether'. The first three sites repress the kinase from adopting an active conformation... PMID:28166054
28. Besides, we found miR-628-5p targeted at and down-regulated the expression of fibroblast growth factor receptor 2 (FGFR2). FGFR2 expressed higher in ovarian cancer tissues and was correlated with worse prognosis. Our findings indicated that miR-628-5pplays an important role in ovarian cancer stem cell driven tumorigenesis. PMID:29229394
29. Mandibular growth in children with FGFR2 mutations is not normal with impairments found in forward sagittal growth and skull base widening PMID:28468153
30. Inhibiting Fgf-R partly reversed alphavbeta3 integrin activity in Mll-Ell+ progenitor cells. PMID:27340869
31. In gastric cancer, FGFR2 protein overexpression predicts gene amplification and poor survival. PMID:27230412
32. Her2, cMet and FGFR2 statuses were profiled in gastric cancer (GC) patients and the -derived tumor xenograft(PDX) models. PMID:28292264
33. We demonstrate that the bent bone dysplasia syndrome mutations in FGFR2 p.M391R and p.Y381D augment the ability of FGFR2 to epigenetically activate rDNA. Mutations p.M391R and p.Y381D activate the p53 nucleolar stress response pathway and alter FGFR2-mediated activation of ribosome biogenesis. PMID:28595297
34. Polyclonal secondary FGFR2 mutations represent an important clinical resistance mechanism to protein kinase inhibitors in patients with FGFR2 fusion-positive cholangiocarcinoma. PMID:28034880
35. CD44 and FGFR2 maintain stemness in gastric cancer by differentially regulating c-Myc transcription. PMID:27107424
36. a novel identical postzygotic activating FGFR2 mutation in two unrelated fetuses with papillomatous pedunculated sebaceous naevus. PMID:27095246
37. Findings suggest fibroblast growth factor receptor 2 (FGFR2) as a therapeutic target for esophagogastric junction (EGJ) adenocarcinoma. PMID:26933914
38. Description of these patients expands the prenatal and postnatal findings of Bent Bone Dysplasia-FGFR2 type and adds to the phenotypic spectrum among all FGFR2 disorders. PMID:27240702
39. Our results imply that the same FGFR2 mutations result in diverse phenotypes, and that genetic studies are recommended not only for obviously affected individuals but also for family members with apparently normal phenotype or non-specific subtle abnormal phenotype. PMID:27683237
40. Liensinine inhibits FGFR2 activity. PMID:28132898
41. FGFR2-ACSL5 fusion is associated with resistance to LY2874455 in FGFR2-amplified gastric cancer . PMID:28122360
42. FGFR2 mutation is associated with endometrial carcinoma progression and abdominopelvic metastasis. PMID:27348297
43. FGFR inhibitors, particularly BGJ398, are therapeutic options for cholangiocarcinoma patients harboring FGFR2-CCDC6 fusions. PMID:27216979
44. High FGFR2 expression is associated with Gastric Cancers. PMID:27197184
45. Two novel FGFR 2 gene missense mutations in Chinese patients with Crouzon syndrome were identified. PMID:27430617
46. Incidence of progression (progressed, recurred or died from disease) of endometrioid endometrial cancer was significantly more prevalent (32/125, 26%) among patients with FGFR2 mutation versus wild type (120/848, 14%; p<0.001, Chi-square test). PMID:28314589
47. We show that this stabilizes the tyrosine and primes it for the catalytic phosphotransfer, and it may lower the activation barrier of the phosphotransfer reaction. Our work demonstrates the value of including dynamic information gleaned from computer simulation in deciphering RTK regulatory function. PMID:28151998
48. We show that the decrease in PI(4,5)P2 level under non-stimulated conditions inhibits PTEN activity leading to the aberrant activation of the oncoprotein Akt. As well as defining a novel mechanism of Akt phosphorylation with important therapeutic consequences, we also demonstrate that differential expression levels of FGFR2, Plc11 and Grb2 correlate with patient survival PMID:26212011
49. High FGFR2 expression was significantly associated with the depth of invasion, lymph-node metastasis, pathological stage, and distant metastasis or recurrent disease in gastric cancer. PMID:28056982
50. fibroblast growth factor receptor 2 overexpression is correlated with decreased survival in most solid tumors, suggesting that the expression status of fibroblast growth factor receptor 2 is a valuable prognostic biomarker and a novel therapeutic target in human solid tumors. PMID:28618942

Show More

Hide All

HGNC: 3689

UNIGENE: Hs.533683

KEGG: hsa:2263

STRING: 9606.ENSP00000410294

OMIM: 101200